Abstract: Nucleic acids encoding factor X? analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg 179 are provided.

Abstract: Factor X&Dgr; analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179, preparations containing these factor X&Dgr; analogues, and processes for the preparation thereof are described.

Abstract: Factor X&Dgr; analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor X&Dgr; analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.

Abstract: A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described.

Abstract: A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described.

Abstract: The present invention relates to methods of producing recombinant molecules including the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of the hepatitis B virus, and to compositions of the molecules. Compositions of the recombinant molecules may include a promoter and a marker gene. Cloning vectors are used to incorporate the recombinant molecules into hosts. Cells infected with the chimeric vaccinia produce high levels of preS1 protein. Isolation and purification of the preS1-containing protein is facilitated by the use of a recombinant molecule in which the myristylation site has been deleted by a modification of the nucleotide sequence. The purified preS1-containing protein is useful for development of vaccines, diagnostic kits and therapies.

Abstract: The present invention relates to methods of producing recombinant molecules including the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of the hepatitis B virus, and to compositions of the molecules. Compositions of the recombinant molecules may include a promoter and a marker gene. Cloning vectors are used to incorporate the recombinant molecules into hosts. Cells infected with the chimeric vaccinia produce high levels of preS1 protein. Isolation and purification of the preS1-containing protein is facilitated by the use of a recombinant molecule in which the myristylation site has been deleted by a modification of the nucleotide sequence. The purified preS1-containing protein is useful for development of vaccines, diagnostic kits and therapies.